Published in Cancer Weekly, October 6th, 2009
Further data from a Phase II double-blind, prospective randomized placebo-controlled study of 125 patients with metastatic prostate cancer was presented by Dr. Wayne Godfrey, Senior Medical Director, BN ImmunoTherapeutics.
The headline data as previously reported showed that patients in the PROSTVAC™ group had a significantly longer median overall survival by 8.5 months compared to the control group. The hazard ratio estimate for overall survival from the study is...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.